Selective TYK2 Inhibitor Compounds With Reduced JAK2 Off-Target Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by TYK2, such as inflammatory bowel disease, autoimmune disorders, and cancer, lack selective inhibitors that minimize off-target effects on other JAK kinases like JAK2, leading to unwanted side effects.
Innovation Solution
Development of compounds that selectively inhibit TYK2 activity, reducing the impact on other JAK kinases, particularly JAK2, to treat conditions like inflammatory bowel disease, autoimmune disorders, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If broad-spectrum JAK inhibitors are used to treat TYK2-mediated conditions, then therapeutic coverage is improved, but off-target effects on other JAK kinases (especially JAK2) increase causing unwanted side effects
Solution Approach 1:
The patent segments the JAK kinase family by developing compounds that selectively target only TYK2 while sparing other JAK kinases (JAK1, JAK2, JAK3). This is achieved through specific molecular结构设计 that exploits unique structural features of TYK2, particularly in the ATP binding pocket and allosteric sites, thereby providing therapeutic coverage for TYK2-mediated conditions without the off-target effects of broad-spectrum inhibitors
Solution Approach 2:
The invention applies local quality by designing inhibitors with specific chemical moieties that interact with unique local features of TYK2. The compounds contain specific substituent patterns at defined positions (e.g., R1, R2, R3, R4 groups) that confer selectivity for TYK2 over other JAK kinases, allowing the inhibitor to recognize and bind selectively to the target enzyme's unique structural characteristics
2Object-affected harmful factors
If selective TYK2 inhibitors are developed to minimize off-target effects, then side effect profile is improved, but development complexity and selectivity requirements increase
Solution Approach 1:
The patent employs parameter changes by systematically varying chemical parameters (substituent types, positions, and combinations) to optimize both selectivity and potency. The invention defines specific parameter ranges for molecular weight, logP, and structural features that balance selectivity for TYK2 with acceptable drug-like properties, thereby managing development complexity through defined chemical space exploration
3Reliability
If JAK2 is inhibited along with TYK2 to achieve broader immunosuppression, then immune modulation efficacy is improved, but risk of thrombotic events and other JAK2-specific adverse events increases
Solution Approach 1:
The patent extracts the TYK2-specific therapeutic effect from the broader JAK inhibition effect by developing highly selective TYK2 inhibitors. This extraction approach isolates the beneficial immune modulation associated with TYK2 inhibition (relevant to psoriasis, IBD, and other autoimmune conditions) while eliminating the harmful thrombotic events and other adverse effects specifically associated with JAK2 inhibition, thereby achieving selective immunosuppression without JAK2-related toxicity
Data Source
AI summary
Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.